Nathan Steven D, Piccari Lucilla, Abman Steven H, Balasubramanian Aparna, Girgis Reda E, Kovacs Gabor, Olschewski Horst, Shlobin Oksana A, Stockbridge Norman, Wort S John, Washko George R, Nikkho Sylvia M
Advanced Lung Disease and Transplant Program Inova Schar Heart and Vascular Institute Falls Church Virginia USA.
Department of Pulmonary Medicine, Hospital del Mar Pulmonary Hypertension Unit Barcelona Spain.
Pulm Circ. 2025 Aug 18;15(3):e70144. doi: 10.1002/pul2.70144. eCollection 2025 Jul.
Chronic obstructive pulmonary disease (COPD) is frequently accompanied by abnormalities of the pulmonary vasculature. This vasculopathy spans the spectrum from mild vascular dysfunction to pulmonary hypertension, which on rare occasions can be severe. Given the worldwide prevalence of COPD, it is conceivable that the morbidity and mortality associated with pulmonary vascular dysfunction have been vastly underappreciated, especially in countries and regions where the infrastructure and resources to define the magnitude of the problem are often limited. This article reflects deliberations of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative (PVRI IDDI) Group 3 Pulmonary Hypertension Workstream on the role of the pulmonary vasculature in COPD. In this introductory paper, we lay the foundation for forthcoming papers by our group, with our ultimate goals being to increase awareness and encourage more research, including clinical trials, to address this unmet need.
慢性阻塞性肺疾病(COPD)常伴有肺血管异常。这种血管病变范围广泛,从轻度血管功能障碍到肺动脉高压,极少数情况下可能会很严重。鉴于COPD在全球的患病率,可想而知,与肺血管功能障碍相关的发病率和死亡率一直未得到充分认识,尤其是在那些界定该问题严重程度的基础设施和资源往往有限的国家和地区。本文反映了肺血管研究所创新药物开发倡议(PVRI IDDI)第3组肺动脉高压工作流对肺血管在COPD中的作用的讨论。在这篇介绍性论文中,我们为我们小组即将发表的论文奠定基础,我们的最终目标是提高认识并鼓励开展更多研究,包括临床试验,以满足这一未被满足的需求。